Alixia

Alixia is pioneering a novel approach to oncology by targeting the tumor as a dynamic ecosystem, addressing the limitations of current precision medicine which benefits only a small fraction of patients. The company's integrated research platform combines biology, biophysics, and computational chemistry to discover 'tumor ecosystem disruptors' that impact multiple cell types within the tumor microenvironment. With a preclinical pipeline focused on cancer and related age-related diseases, Alixia is led by a team with strong scientific and operational expertise, positioning itself to tackle the complex challenge of therapeutic resistance.

Integrated research platform combining biology, biophysics, and computational chemistry to study interactions within the tumor microenvironment. Aims to discover small molecule 'tumor ecosystem disruptors' that target metabolic and inflammatory triggers across multiple cell types (cancer cells, fibroblasts, immune cells) to collapse tumor ecosystems and overcome drug resistance.

Alixia competes in the broad and competitive field of tumor microenvironment modulation, which includes companies targeting specific stromal cell types, cytokines, or metabolic pathways. Its key differentiation is the holistic 'ecosystem disruptor' approach aiming for a multi-target effect within the TME, as opposed to targeting a single specific component.